Abstract
The bone marrow (BM) is composed of the non-adherent hematopoietic and adherent stromal cell compartment. This adherent BM stromal cell fraction contains pluripotent mesenchymal stem cells (MSCs) and differentiated mesenchymal BM stromal cells. The MSCs self-renew by proliferation while maintaining their stem-cell phenotype and give rise to the differentiated stromal cells which belong to the osteogenic, chondrogenic, adipogenic, myogenic and fibroblastic lineages. A more primitive adherent stem cell was recently identified, the multipotent adult progenitor cell (MAPC) or mesodermal progenitor cell, which co-purifies with MSCs. These MAPCs differentiate into MSCs, endothelial, epithelial and even hematopoietic cells. BM stroma cells, including the primitive pluripotent MSCs and MAPCs, are attractive targets for cell and gene therapy. The BM stromal cell population and its multipotent stem cells can be engineered to secrete a series of different proteins in vitro and in vivo that could potentially tre at a variety of serum protein deficiencies and other genetic or acquired diseases, including bone, cartilage and BM stromal disorders or even cancer.
Keywords: Bone Marrow, Stromal Cells, Gene Therapy, Growth hormone, Osteogenesis imperfecta, Granulocyte-colony
Current Gene Therapy
Title: Bone Marrow Stromal Cells as Targets for Gene Therapy
Volume: 2 Issue: 2
Author(s): An Van Damme, Thierry Vanden Driessche, Desire Collen and Marinee K.L. Chuah
Affiliation:
Keywords: Bone Marrow, Stromal Cells, Gene Therapy, Growth hormone, Osteogenesis imperfecta, Granulocyte-colony
Abstract: The bone marrow (BM) is composed of the non-adherent hematopoietic and adherent stromal cell compartment. This adherent BM stromal cell fraction contains pluripotent mesenchymal stem cells (MSCs) and differentiated mesenchymal BM stromal cells. The MSCs self-renew by proliferation while maintaining their stem-cell phenotype and give rise to the differentiated stromal cells which belong to the osteogenic, chondrogenic, adipogenic, myogenic and fibroblastic lineages. A more primitive adherent stem cell was recently identified, the multipotent adult progenitor cell (MAPC) or mesodermal progenitor cell, which co-purifies with MSCs. These MAPCs differentiate into MSCs, endothelial, epithelial and even hematopoietic cells. BM stroma cells, including the primitive pluripotent MSCs and MAPCs, are attractive targets for cell and gene therapy. The BM stromal cell population and its multipotent stem cells can be engineered to secrete a series of different proteins in vitro and in vivo that could potentially tre at a variety of serum protein deficiencies and other genetic or acquired diseases, including bone, cartilage and BM stromal disorders or even cancer.
Export Options
About this article
Cite this article as:
Damme Van An, Driessche Vanden Thierry, Collen Desire and Chuah K.L. Marinee, Bone Marrow Stromal Cells as Targets for Gene Therapy, Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605645
DOI https://dx.doi.org/10.2174/1566523024605645 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents in Cancer Stem Cells
Recent Patents on Biomarkers Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Current Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Proliferative Compounds for the Prevention of Restenosis: Anti-Restenotic Mechanisms of Paclitaxel Action
Current Pharmaceutical Design <i>Achillea millefolium</i> E.Mey: Phytochemistry and Pharmacological Profile
Current Traditional Medicine High Throughput Metabolomics in Clinical Studies: Review and New Applications to Remote Ischemic Preconditioning
Current Topics in Medicinal Chemistry The Role of Natural Killer T Cells in Atherosclerosis
Current Immunology Reviews (Discontinued) Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry Hesperidin Potentiates Ghrelin Signaling
Recent Patents on Food, Nutrition & Agriculture Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy RGD Peptide–mediated Molecular Imaging for Targeting Integrin Alpha(v) Beta(3) in Tumors: A Review
Current Medical Imaging Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology